Extreme Short Positioning in SLS
SELLAS Life Sciences Group (SLS) is heading into its latest earnings print with one of the most aggressive short-interest setups in the small-cap biotech sector. According to Ortex data, approximately 39% of the company's free float is currently held short. This level of bearish conviction is compounded by a lending market that is described as 'almost fully locked,' indicating that borrowable shares are becoming increasingly scarce for those looking to initiate or maintain short positions. The stock has already faced significant downward pressure, falling 33% recently, as the market prices in the high-risk nature of the upcoming results.
Signal data sourced from Ortex. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.